A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Small Cell Lung Cancer
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- AbbVie
- Enrolment target
- 180
- Started
- 25 November 2025
- Main results due
- April 2029
- Study sites
- 68
- Registry updated
- 23 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy. * Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment. * Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). * Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry. Exclusion Criteria: * Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC). * Known active/symptomatic central nervous system (CNS) metastases should be excluded. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded. * Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.
What this study is about
In the sponsor’s own words, from the registry.
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).
ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide.
In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Study sites(68)
Yale University School of Medicine /ID# 278181
New Haven, Connecticut, United States
Recruiting
University of Florida College of Medicine /ID# 277496
Gainesville, Florida, United States
Recruiting
Ocala Oncology Center /ID# 278269
Ocala, Florida, United States
Recruiting
Moffitt Cancer Center /ID# 277573
Tampa, Florida, United States
Recruiting
Fort Wayne Medical Oncology And Hematology /ID# 277336
Fort Wayne, Indiana, United States
Recruiting
Baptist Health Lexington /ID# 277729
Lexington, Kentucky, United States
Recruiting
Dana-Farber Cancer Institute /ID# 277732
Boston, Massachusetts, United States
Recruiting
Missouri Cancer Associates /ID# 278299
Columbia, Missouri, United States
Recruiting
University Hospitals Cleveland Medical Center /ID# 277556
Cleveland, Ohio, United States
Recruiting
The University of Texas MD Anderson Cancer Center /ID# 277929
Houston, Texas, United States
Recruiting
Virginia Cancer Specialists - Fairfax /ID# 278298
Fairfax, Virginia, United States
Recruiting
Grand Hopital de Charleroi - Les Viviers /ID# 276897
Charleroi, Hainaut, Belgium
Recruiting
Groupe Sante CHC - Clinique du MontLegia /ID# 276783
Liège, Liege, Belgium
Recruiting
Jessa Ziekenhuis - Campus Virga Jesse /ID# 276781
Hasselt, Limburg, Belgium
Recruiting
AZ Maria Middelares /ID# 277027
Ghent, Oost-Vlaanderen, Belgium
Recruiting
Cancer Hospital - Chinese Academy of Medical Sciences /ID# 277167
Beijing, Beijing Municipality, China
Recruiting
Henan Cancer Hospital /ID# 277059
Zhengzhou, Henan, China
Recruiting
Union Hospital Tongji Medical College /ID# 277912
Wuhan, Hubei, China
Recruiting
The First affiliated hospital of Nanchang University /ID# 277247
Nanchang, Jiangxi, China
Recruiting
Shanghai East Hospital /ID# 277111
Shanghai, Shanghai Municipality, China
Recruiting
Shanghai Pulmonary Hospital /ID# 276960
Shanghai, Shanghai Municipality, China
Recruiting
West China Hospital of Sichuan University /ID# 277852
Chengdu, Sichuan, China
Recruiting
Lungenfachklinik Immenhausen /ID# 278005
Immenhausen, Hesse, Germany
Recruiting
Universitaetsklinikum Giessen und Marburg GmbH /ID# 277466
Marburg, Hesse, Germany
Recruiting
Evangelische Lungenklinik Berlin /ID# 277094
Berlin, Germany
Recruiting
Meir Medical Center /ID# 277292
Kefar Sava, Central District, Israel
Recruiting
Assuta Ashdod Medical Center /ID# 276661
Ashdod, Southern District, Israel
Recruiting
The Chaim Sheba Medical Center /ID# 276660
Ramat Gan, Tel Aviv, Israel
Recruiting
Rambam Health Care Campus- Haifa /ID# 276663
Haifa, Israel
Recruiting
Hadassah Medical Center-Hebrew University /ID# 276662
Jerusalem, Israel
Recruiting
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 276792
Rome, Roma, Italy
Recruiting
Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 276789
Orbassano, Torino, Italy
Recruiting
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 277744
Roma, Italy
Recruiting
National Cancer Center Hospital East /ID# 277239
Kashiwa-shi, Chiba, Japan
Recruiting
Shizuoka Cancer Center /ID# 277243
Sunto-gun, Shizuoka, Japan
Recruiting
Tokyo Metropolitan Komagome Hospital /ID# 277335
Bunkyo Ku, Tokyo, Japan
Recruiting
National Cancer Center Hospital /ID# 277237
Chuo-Ku, Tokyo, Japan
Recruiting
Wakayama Medical University Hospital /ID# 277260
Wakayama, Wakayama, Japan
Recruiting
Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeyla /ID# 276907
Poznan, Greater Poland Voivodeship, Poland
Recruiting
Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 276910
Lublin, Lublin Voivodeship, Poland
Recruiting
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 277112
Warsaw, Masovian Voivodeship, Poland
Recruiting
University Clinical Center Serbia /ID# 277007
Belgrade, Beograd, Serbia
Recruiting
Clinical Hospital Center - Bezanijska Kosa /ID# 277013
Belgrade, Beograd, Serbia
Recruiting
University Clinical Center Nis /ID# 277180
Niš, Nisavski Okrug, Serbia
Recruiting
Institute For Pulmonary Diseases Of Vojvodina /ID# 277003
Kamenitz, Sremski Okrug, Serbia
Recruiting
University Clinical Center Kragujevac /ID# 277179
Kragujevac, Sumadijski Okrug, Serbia
Recruiting
National Cancer Center /ID# 277434
Goyang-si, Gyeonggido, South Korea
Recruiting
Chungbuk National University Hospital /ID# 277429
Cheongju-si, North Chungcheong, South Korea
Recruiting
Seoul National University Hospital /ID# 277271
Seoul, Seoul Teugbyeolsi, South Korea
Recruiting
Yonsei University Health System Severance Hospital /ID# 277597
Seoul, Seoul Teugbyeolsi, South Korea
Recruiting
Asan Medical Center /ID# 277603
Seoul, Seoul Teugbyeolsi, South Korea
Recruiting
Samsung Medical Center /ID# 277615
Seoul, Seoul Teugbyeolsi, South Korea
Recruiting
Hospital Regional Universitario de Malaga /ID# 276927
Málaga, Andalusia, Spain
Recruiting
Complejo Hospitalario Universitario A Coruna /ID# 276922
A Coruña, Spain
Recruiting
Hospital Clinic de Barcelona /ID# 276878
Barcelona, Spain
Recruiting
Hospital General Universitario Gregorio Maranon /ID# 276877
Madrid, Spain
Recruiting
Hospital Universitario 12 de Octubre /ID# 277251
Madrid, Spain
Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277267
Kaohsiung City, Taiwan
Recruiting
Kaohsiung Chang Gung Memorial Hospital /ID# 277725
Kaohsiung City, Taiwan
Recruiting
Chung Shan Medical University Hospital /ID# 277660
Taichung, Taiwan
Recruiting
Showing 60 of 68 sites — filter to narrow it down. 68 of the 68 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07155174. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me